Integrated Biopharma, Inc.
INBP
$0.31
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.02% | 4.67% | 3.18% | -0.47% | -0.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.02% | 4.67% | 3.18% | -0.47% | -0.70% |
| Cost of Revenue | 5.08% | 1.21% | -0.25% | -1.62% | -0.38% |
| Gross Profit | 43.20% | 49.94% | 51.64% | 13.53% | -4.36% |
| SG&A Expenses | -2.50% | -3.12% | -2.79% | -6.01% | -7.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.53% | 0.90% | -0.44% | -1.95% | -0.96% |
| Operating Income | 704.78% | 2,645.83% | 478.33% | 2,108.33% | 109.17% |
| Income Before Tax | 669.40% | 3,085.71% | 494.31% | 2,052.63% | 168.00% |
| Income Tax Expenses | 703.85% | 1,083.02% | 3,193.75% | 304.17% | 16.42% |
| Earnings from Continuing Operations | 621.43% | 1,181.03% | 341.04% | 841.38% | 429.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 621.43% | 1,181.03% | 341.04% | 841.38% | 429.41% |
| EBIT | 704.78% | 2,645.83% | 478.33% | 2,108.33% | 109.17% |
| EBITDA | 319.00% | 783.20% | 3,155.17% | 196.01% | 18.47% |
| EPS Basic | 624.32% | 1,164.10% | 338.76% | 815.00% | 408.33% |
| Normalized Basic EPS | 658.93% | 3,084.62% | 505.26% | 2,037.50% | 154.55% |
| EPS Diluted | 616.22% | 1,156.41% | 337.98% | 815.00% | 408.33% |
| Normalized Diluted EPS | 701.92% | 2,620.00% | 490.91% | 2,257.14% | 147.62% |
| Average Basic Shares Outstanding | 0.77% | 0.47% | 0.42% | 0.49% | 0.39% |
| Average Diluted Shares Outstanding | 2.11% | 1.63% | 0.41% | -0.45% | -0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |